Profilo
Mr. Sébastien Laliberté is Financial Analyst at Sectoral Asset Management, Inc.
Mr. Laliberté assumes analytical coverage for Generic and Specialty Pharma companies.
He cumulates 15 years of experience in drug discovery as a Research Scientist at Merck, AstraZeneca/OmegaChem and the Institute for Research in Immunology and Cancer of Montreal University.
He was involved in many research projects leading to multiple clinical candidates.
He received his BS in Pharmaceutical Chemistry and MS in Organic Chemistry from the University of Sherbrooke and an MBA with a concentration in Finance from HEC Montréal.
Precedenti posizioni note di Sébastien Laliberté
| Società | Posizione | Fine |
|---|---|---|
Insitut de Recherche en Immunologie et en Cancérologie
Insitut de Recherche en Immunologie et en Cancérologie Miscellaneous Commercial ServicesCommercial Services Engages in research and development in immunology and cancer | Corporate Officer/Principal | - |
Sectoral Asset Management, Inc.
Sectoral Asset Management, Inc. Investment ManagersFinance Sectoral aims to achieve superior returns for their investors by concentrating on primary research of company fundamentals and in-depth due diligence on companies to assess their scientific, business, financial and ESG aspects. The firm offers four Healthcare strategies: Global Healthcare, Emerging Healthcare, Small & Mid-Cap Healthcare & Biotech. They employ a bottom-up investment approach that can be categorized as Growth at a Reasonable Price (GARP). | Analyst-Equity | - |
Formazione di Sébastien Laliberté
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Sectoral Asset Management, Inc.
Sectoral Asset Management, Inc. Investment ManagersFinance Sectoral aims to achieve superior returns for their investors by concentrating on primary research of company fundamentals and in-depth due diligence on companies to assess their scientific, business, financial and ESG aspects. The firm offers four Healthcare strategies: Global Healthcare, Emerging Healthcare, Small & Mid-Cap Healthcare & Biotech. They employ a bottom-up investment approach that can be categorized as Growth at a Reasonable Price (GARP). | Finance |
University of Sherbrooke
University of Sherbrooke Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
HEC Montréal
HEC Montréal Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Insitut de Recherche en Immunologie et en Cancérologie
Insitut de Recherche en Immunologie et en Cancérologie Miscellaneous Commercial ServicesCommercial Services Engages in research and development in immunology and cancer | Commercial Services |
















